
|Videos|April 29, 2015
Impact of Bevacizumab in Ovarian Cancer
Author(s)Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5


















